Verrica Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Verrica Pharmaceuticals

09/08/2023 14:32

* Verrica Pharmaceuticals Inc  VRCA.OQ  reported a quarterly
adjusted loss of 24 cents​​ per share for the quarter ended in
June. The mean expectation of five analysts for the quarter was
for a loss of 21 cents per share.
    * Revenue fell 15% to $182.00 thousand from a year ago;
analysts
expected $72.00 thousand. 
    * Verrica Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 24 cents​.
    * The mean earnings estimate of analysts had risen by
about 3% in
the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Verrica Pharmaceuticals Inc shares had fallen by 8.3% this
quarter and gained 92.4% so far this year.
    * The company reported a quarterly loss of $10.99 million.
    * Wall Street's median 12-month price target for Verrica
Pharmaceuticals Inc is $13.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 9 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.21          -0.24          Missed
 Mar. 31 2023      -0.19          -0.15          Beat
 Dec. 31 2022      -0.19          -0.14          Beat
 Sep. 30 2022      -0.11          0.03           Beat